Crestline Management LP bought a new stake in shares of Kadmon Holdings, Inc. (NYSE:KDMN) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 600,228 shares of the company’s stock, valued at approximately $2,011,000. Crestline Management LP owned 0.76% of Kadmon as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the company. Wells Fargo & Company MN grew its position in shares of Kadmon by 17.0% during the 2nd quarter. Wells Fargo & Company MN now owns 60,033 shares of the company’s stock valued at $234,000 after acquiring an additional 8,742 shares during the period. Goldman Sachs Group Inc. purchased a new stake in shares of Kadmon during the 2nd quarter valued at approximately $114,000. Bank of New York Mellon Corp purchased a new stake in shares of Kadmon during the 3rd quarter valued at approximately $119,000. Renaissance Technologies LLC purchased a new stake in shares of Kadmon during the 1st quarter valued at approximately $158,000. Finally, Old West Investment Management LLC purchased a new stake in shares of Kadmon during the 3rd quarter valued at approximately $169,000. 51.90% of the stock is owned by hedge funds and other institutional investors.

Shares of Kadmon Holdings, Inc. (NYSE:KDMN) traded down $0.09 during mid-day trading on Tuesday, hitting $3.55. 1,110,200 shares of the company were exchanged, compared to its average volume of 289,980. Kadmon Holdings, Inc. has a 12 month low of $2.05 and a 12 month high of $5.93.

Kadmon (NYSE:KDMN) last announced its quarterly earnings results on Thursday, November 9th. The company reported ($0.42) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.38) by ($0.04). The company had revenue of $2.28 million for the quarter, compared to the consensus estimate of $5.69 million. During the same quarter in the prior year, the firm earned ($4.24) EPS. The company’s quarterly revenue was down 60.0% compared to the same quarter last year. research analysts predict that Kadmon Holdings, Inc. will post -1.61 earnings per share for the current fiscal year.

A number of analysts recently commented on the stock. Zacks Investment Research upgraded shares of Kadmon from a “sell” rating to a “hold” rating in a research note on Tuesday, November 21st. HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of Kadmon in a research note on Friday, November 17th. Finally, WBB Securities cut shares of Kadmon from a “hold” rating to a “sell” rating and set a $3.00 price target on the stock. in a research note on Monday, October 9th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. Kadmon has a consensus rating of “Hold” and a consensus price target of $9.75.

COPYRIGHT VIOLATION WARNING: This article was posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at

Kadmon Company Profile

Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.

Want to see what other hedge funds are holding KDMN? Visit to get the latest 13F filings and insider trades for Kadmon Holdings, Inc. (NYSE:KDMN).

Institutional Ownership by Quarter for Kadmon (NYSE:KDMN)

Receive News & Ratings for Kadmon Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon Holdings Inc. and related companies with's FREE daily email newsletter.